PHAR

Pharming Group N.V. NASDAQ Listed Dec 23, 2020

Healthcare ·Biotechnology ·NL · pharming.com

$12.00

Mkt Cap $842.8M

52w Low $8.69 26.2% of range 52w High $21.34

50d MA $16.38 200d MA $15.57

P/E (TTM) 424.5x

EV/EBITDA 40.2x

P/B 4.4x

Debt/Equity 0.4x

ROE —

P/FCF 25.6x

RSI (14) —

ATR (14) —

Beta 0.12

50d MA $16.38

200d MA $15.57

Avg Volume 23.5K

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

SIC Code

2834

CIK (SEC)

1828316

Phone

31 71 524 7400

Darwinweg 24 · Leiden, P7 2333 CR · NL

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	0.15	0.07	-53.3%	15.14	+0.0%	-4.2%	+6.3%	+0.4%	-1.5%	+1.4%	—
Nov 6, 2025	AMC	0.05	0.10	+100.0%	14.70	+9.5%	+5.0%	+13.7%	-10.0%	+8.6%	+2.7%	—
Jul 31, 2025	AMC	-0.10	0.06	+160.0%	11.11	-3.6%	-1.4%	+11.8%	+1.9%	-1.5%	-1.1%	—
May 8, 2025	AMC	-0.25	-0.22	+12.0%	10.01	+1.0%	+0.2%	-3.2%	+3.0%	-8.5%	-0.2%	—
Mar 13, 2025	AMC	0.07	0.05	-28.6%	8.74	-0.9%	+2.4%	-1.7%	+0.0%	+1.5%	+0.0%	—
Oct 24, 2024	AMC	0.01	-0.02	-300.0%	8.30	+5.7%	+4.8%	+1.6%	-1.8%	+2.1%	+0.6%	—
Aug 1, 2024	AMC	-0.00	-0.01	-400.0%	7.63	+1.2%	-5.0%	+4.6%	+6.7%	-2.3%	-0.6%	—
May 8, 2024	AMC	0.01	-0.19	-2000.0%	9.50	-1.8%	+2.0%	+3.2%	-6.6%	+3.1%	-0.4%	—
Mar 14, 2024	AMC	0.05	-0.03	-160.0%	10.92	+4.6%	+5.2%	+0.1%	-4.3%	+2.5%	-3.7%	—
Oct 26, 2023	AMC	0.13	0.05	-61.5%	10.92	+6.1%	+1.4%	-1.5%	+8.8%	-0.7%	+1.9%	—
Aug 3, 2023	AMC	-0.02	0.02	+200.0%	12.50	+0.0%	+0.0%	-4.5%	+0.0%	+2.8%	+0.0%	—
May 11, 2023	AMC	-0.01	-0.17	-1600.0%	10.21	+11.4%	+8.6%	+4.7%	+1.9%	-1.1%	+1.8%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.01	$15.84	-1.1%	-0.2%	+1.6%	+0.5%	+0.0%	-1.8%
Mar 13	Oppenheimer	Maintains	Outperform → Outperform	—	$15.14	$15.14	+0.0%	-4.2%	+6.3%	+0.4%	-1.5%	+1.4%
Mar 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.93	$8.67	-2.9%	-1.0%	-0.1%	-1.2%	+0.7%	-1.5%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.93	$8.93	+0.0%	+0.0%	-1.0%	-0.1%	-1.2%	+0.7%
Mar 14	Oppenheimer	Maintains	Outperform → Outperform	—	$8.74	$8.66	-0.9%	+2.4%	-1.7%	+0.0%	+1.5%	+0.0%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.74	$8.66	-0.9%	+2.4%	-1.7%	+0.0%	+1.5%	+0.0%
Dec 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.89	$8.90	+0.1%	-1.0%	-3.5%	+5.3%	+1.8%	+14.6%
Dec 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.98	$8.91	-0.8%	-1.0%	-1.0%	-3.5%	+5.3%	+1.8%
Dec 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.74	$9.59	+9.7%	+6.1%	+0.5%	-3.6%	-1.0%	-1.0%
Oct 28	Oppenheimer	Maintains	Outperform → Outperform	—	$8.70	$8.68	-0.2%	+1.6%	-1.8%	+2.1%	+0.6%	-4.4%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.96	$8.29	-7.5%	-7.4%	+4.8%	+1.6%	-1.8%	+2.1%
Oct 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.51	$8.77	+3.1%	+2.2%	-0.2%	-0.8%	+6.4%	-2.7%
Oct 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.65	$8.63	-0.2%	+1.5%	-3.2%	+0.1%	+2.2%	-0.2%
Sep 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.70	$7.94	+3.1%	+4.3%	+5.7%	-2.8%	+4.1%	-5.7%
Aug 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.33	$8.21	-1.4%	-8.4%	-5.0%	+4.6%	+6.7%	-2.3%
May 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.93	$8.88	-0.6%	+2.5%	+1.0%	-5.3%	-12.2%	+13.7%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.11	$11.06	-0.5%	-1.7%	+5.2%	+0.1%	-4.3%	+2.5%
Mar 28	Oppenheimer	Maintains	Outperform → Outperform	—	$12.26	$12.39	+1.1%	+3.6%	+7.1%	-4.8%	+4.2%	-5.4%
Mar 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.96	$12.72	-15.0%	-18.0%	+3.6%	+7.1%	-4.8%	+4.2%
Feb 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.08	$11.15	+0.6%	+12.4%	-5.2%	-0.5%	+0.9%	+3.2%
Feb 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.13	$11.90	-9.4%	-10.5%	-6.1%	+0.4%	+12.4%	-5.2%

Data updated apr 26, 2026 7:32pm · Source: massive.com